Tolerability and efficacy of the intestinal phosphate binder Lantharenol® in cats

Abstract

BackgroundTolerability and efficacy of the intestinal phosphate binder Lantharenol® (lanthanum carbonate octahydrate) were tested in two prospective, randomized and negative controlled laboratory studies with healthy adult cats fed commercial maintenance diets non-restricted in phosphorus. In the first study, the maximal tolerated dose was determined. Starting from a dose of 0.125 g/kg body weight mixed with the daily feed ration, the dose of Lantharenol® was doubled every other week until signs of intolerability were observed (N = 10 cats compared to 5 untreated controls). In the second study, the effects of feed supplementation for two weeks with approximately 2, 6, and 20% of the maximal tolerated dose on phosphorus excretion patterns and balance were assessed (N = 8 cats per group).ResultsLantharenol® was found to be safe and well tolerated up to the dose of 1 g/kg bodyweight, corresponding to a concentration of 84 g Lantharenol®/kg complete feed, defined as dry matter with a standard moisture content of 12%. Feed supplementation for two weeks with approximately 2-20% of this dosage (i.e., 1.6, 4.8, and 16 g/kg complete feed) resulted in a shift from urinary to faecal phosphorus excretion. Apparent phosphorus digestibility was dose-dependently reduced compared to the control group fed with diet only (N = 8).ConclusionsThe feed additive was well accepted and tolerated by all cats. Therefore, Lantharenol® presents a well tolerated and efficacious option to individually tailor restriction of dietary phosphorus as indicated, for instance, in feline chronic kidney disease.

Nonuraemic nonfatal idiopathic calciphylaxis in a kitten

“…Lantharenol ® , a noncalcium‐based phosphate‐binding food additive, was given as described for uraemic cats . This is one of the treatment strategies in calciphylactic human patients with hyperphosphataemia .…”

ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease

“…Several agents can be used for this purpose (see Table 4). 53,[67][68][69] There are no studies comparing different phosphate binders in cats with CKd, but all are likely to be efficacious. 53 offering alternative binders when needed may be appropriate, as palatability of the phosphate binders varies.…”

Assessment of the application for renewal of authorisation of Lantharenol® (lanthanum carbonate octahydrate) for cats

“…From the literature search performed (see also paragraph under Section 3.2), only four scientific papers were chosen as being potentially relevant to the safety assessment. The FEEDAP Panel considered these four papers and found that one of them (Schmidt et al, 2012) in an unpublished formhad been already assessed in the previous application. The other three papers (DiBartola, 2010;Thom et al, 2013;Bernachon et al, 2014) did not provide any relevant additional information on the safety of the product when used for cats.…”